{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-035502","form_type":"8-K","ticker":"DMAA","cik":"0002028614","company_name":"Drugs Made In America Acquisition Corp.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.038173+00:00","generated_at":"2026-05-15T08:43:30.072600+00:00","sec_items":["1.01","8.01","2.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"DMAA SPAC enters $100K convertible bridge as first step of $500K financing; identifies AI/cybersecurity target","bullets":["BV Advisory Partners provides $100K convertible note (up to $500K total) for compliance and transaction expenses.","Note converts at 35% discount to post-merger market value, matures in 6 months, no interest, no trust account claim.","Investor introduced potential target: enterprise AI/ML, quantum analytics, cybersecurity platform (Power Analytics Global).","Company to pursue replacement sponsor and provide investor ≥40% sponsor-level economics; no definitive agreement yet.","Proceeds used for audit, Nasdaq, legal, proxy, extension fees."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-035502","json":"https://secwatch.observer/filing/0001213900-26-035502.json","markdown":"https://secwatch.observer/filing/0001213900-26-035502.md","text":"https://secwatch.observer/filing/0001213900-26-035502.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/ea0283803-8k_drugs.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:43:30.072600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8eed0391a2b52895c936e59837325fed7b4651bc","claim":"Drugs Made In America Acquisition Corp. incurred convertible notes of $100,000 with BV Advisory Partners, LLC at does not bear interest maturing six months from the date of issuance.","evidence_excerpt":"On March 23, 2026, Drugs Made In America Acquisition Corp. (the \" Company \") issued an interim convertible note (the \" Interim Note \") to BV Advisory Partners, LLC (the \" Investor \") in the principal amount of $100,000 (the \" Interim Loan \").","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm","confidence":0.9},{"claim_id":"9ae2c556b1d83e6a1b48e85660ae1ed86fb8c2d3","claim":"Drugs Made In America Acquisition Corp. entered into Investment Agreement with BV Advisory Partners, LLC valued at $500,000 (effective 2026-03-23).","evidence_excerpt":"On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm","confidence":0.7},{"claim_id":"c153f39cf8337af428e114c6eeaaae227ace1f3a","claim":"Drugs Made In America Acquisition Corp. entered into Interim Note with BV Advisory Partners, LLC valued at $100,000 (effective 2026-03-23).","evidence_excerpt":"issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001193125-26-251789","ticker":"GIPR","company_name":"GENERATION INCOME PROPERTIES, INC.","filed_at":"2026-06-01T21:27:59+00:00","headline":"Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit","event_type":"other_material","sec_items":["1.01","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251789","json":"https://secwatch.observer/filing/0001193125-26-251789.json","markdown":"https://secwatch.observer/filing/0001193125-26-251789.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/0001193125-26-251789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/gipr-20260528.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm","comparable_excerpt":"In connection with the Offering, on May 28, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC, as placement agent","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1651721/000119312526251789/0001193125-26-251789-index.htm"}},{"accession":"0000790816-26-000019","ticker":null,"company_name":"BRANDYWINE OPERATING PARTNERSHIP, L.P.","filed_at":"2026-06-01T20:30:42+00:00","headline":"Brandywine extends revolver maturity to Dec 2026; shareholders OK 5M share increase for LTIP","event_type":"other_material","sec_items":["1.01","2.03","5.02","5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 2.03, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000790816-26-000019","json":"https://secwatch.observer/filing/0000790816-26-000019.json","markdown":"https://secwatch.observer/filing/0000790816-26-000019.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1060386/000079081626000019/0000790816-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/790816/000079081626000019/bdn-20260528.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm","comparable_excerpt":"tnership, L.P., a Delaware limited partnership (the “Operating Partnership” and, together with the Company, the “Borrowers”) extended the maturity date of the Borrowers’ revolving credit facility (the “Revolving Credit Facility”) provided under the Borrowers’ Second Amended and Restated Credit Agreement, dated as of June 30, 2022 (the “Credit Agreement”), by and among the Borrowers, Bank of America, N.A., as administrative agent and lender, and the other agents and lenders party thereto, for a period of six months from June 30, 2026 to December 30, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1060386/000079081626000019/0000790816-26-000019-index.htm"}},{"accession":"0001437749-26-018930","ticker":"CPSH","company_name":"CPS TECHNOLOGIES CORP/DE/","filed_at":"2026-06-01T13:35:50+00:00","headline":"CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share","event_type":"other_material","sec_items":["1.01","5.03","8.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-018930","json":"https://secwatch.observer/filing/0001437749-26-018930.json","markdown":"https://secwatch.observer/filing/0001437749-26-018930.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/814676/000143774926018930/0001437749-26-018930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/814676/000143774926018930/cpsh20260528_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm","comparable_excerpt":"On May 27, 2026, CPS Technologies Corp. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional investors (the “Investors”) for the sale by the Company of 1,200,000 shares (the “Shares”) of its Common Stock, par value $0.01 per share (“Common Stock”), in a registered direct offering (the “Offering”), at a purchase price of $8.00 per share.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/814676/000143774926018930/0001437749-26-018930-index.htm"}},{"accession":"0001213900-26-063767","ticker":"BJDX","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2026-06-02T10:30:41+00:00","headline":"Bluejay Diagnostics partners with Argonaut for US-based Symphony platform manufacturing","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063767","json":"https://secwatch.observer/filing/0001213900-26-063767.json","markdown":"https://secwatch.observer/filing/0001213900-26-063767.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026063767/0001213900-26-063767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026063767/ea0293118-8k_bluejay.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm","comparable_excerpt":"On May 27, 2026, Bluejay Diagnostics, Inc. (the “Company”) entered into an agreement and statement of work (together, the “Agreement”) with Argonaut Manufacturing Services c/o Argonaut, Inc. (“Argonaut”) regarding the provision by Argonaut to the Company of certain manufacturing services to support the Company’s SymphonyTM platform.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390026063767/0001213900-26-063767-index.htm"}},{"accession":"0001140361-26-023619","ticker":"GNK","company_name":"GENCO SHIPPING & TRADING LTD","filed_at":"2026-06-02T10:01:31+00:00","headline":"Genco Shipping amends shareholder rights plan, eliminates 'Acting in Concert' definition","event_type":"other_material","sec_items":["1.01","3.03","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023619","json":"https://secwatch.observer/filing/0001140361-26-023619.json","markdown":"https://secwatch.observer/filing/0001140361-26-023619.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326200/000114036126023619/0001140361-26-023619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326200/000114036126023619/ef20075333_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm","comparable_excerpt":"On June 2, 2026, Genco Shipping & Trading Limited (the “ Company ”) entered into the Third Amendment to Shareholders Rights Agreement (the “ Third Amendment ”) to amend the Shareholder Rights Agreement, dated as of October 1, 2025 between the Company and Computershare Inc., as amended to date (the “ Rights Agreement ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1326200/000114036126023619/0001140361-26-023619-index.htm"}},{"accession":"0001213900-26-063576","ticker":"LOKV","company_name":"Live Oak Acquisition Corp. V","filed_at":"2026-06-01T21:00:23+00:00","headline":"Live Oak enters Forward Purchase Agreement to back Teamshares merger, up to 4M shares at ~$10.54","event_type":"other_material","sec_items":["1.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063576","json":"https://secwatch.observer/filing/0001213900-26-063576.json","markdown":"https://secwatch.observer/filing/0001213900-26-063576.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2048951/000121390026063576/0001213900-26-063576-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2048951/000121390026063576/ea0292781-8k425_liveoak5.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm","comparable_excerpt":"On June 1, 2026, Live Oak Acquisition Corp. V, a Cayman Island exempted company (\" Live Oak \"), and HB Strategies LLC (\" Seller \" or \" FPA Investor \") entered into an agreement (the \" Forward Purchase Agreement \") for an OTC Prepaid Share Forward Transaction-Optional Early Termination (the \" Forward Purchase Transaction \") in connection with Live Oak’s proposed initial business combination (the \" Business Combination \") with Teamshares Inc., a Delaware corporation (\" Teamshares \" and the surviving public company following consummation of the Business Combination, the \" Combined Company \"), which is the subject of the previously-disclosed Agreement and Plan of Merger entered into by Live Oak and Teamshares as of November 14, 2025 (as amended as of April 1, 2026, and as may be further amended or supplemented from time to time, the \" Merger Agreement \").","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2048951/000121390026063576/0001213900-26-063576-index.htm"}},{"accession":"0001683168-26-004423","ticker":"CITR","company_name":"CitroTech Inc.","filed_at":"2026-06-01T20:15:28+00:00","headline":"CitroTech exchanges all Series A Preferred for Series C Convertible; BoltRock gets board rights","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004423","json":"https://secwatch.observer/filing/0001683168-26-004423.json","markdown":"https://secwatch.observer/filing/0001683168-26-004423.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/894556/000168316826004423/0001683168-26-004423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894556/000168316826004423/citro_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm","comparable_excerpt":"On May 28, 2026, CitroTech Inc., a Wyoming corporation (the “Company”), entered into Stock Exchange and Stockholders Agreements (the “Exchange Agreements”) with the holders (the “Holders”) of the Company’s outstanding Series A Preferred Stock","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/894556/000168316826004423/0001683168-26-004423-index.htm"}},{"accession":"0001683168-26-004424","ticker":"LTRX","company_name":"LANTRONIX INC","filed_at":"2026-06-01T20:15:28+00:00","headline":"Lantronix prices $30M common stock offering at $7.20/share; net proceeds ~$32.3M","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004424","json":"https://secwatch.observer/filing/0001683168-26-004424.json","markdown":"https://secwatch.observer/filing/0001683168-26-004424.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1114925/000168316826004424/0001683168-26-004424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1114925/000168316826004424/lantronix_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 23, 2026, Drugs Made In America Acquisition Corp. (the “ Company ”) issued an interim convertible note (the “ Interim Note ”) to BV Advisory Partners, LLC (the “ Investor ”) in the principal amount of $100,000 (the “ Interim Loan ”). The Interim Loan represents an initial loan towards a contemplated $500,000 financing (the “ Financing ”) pursuant to the Definitive Interim Investment and Sponsor Transition Agreement dated March 23, 2026 (the “ Investment Agreement ”)","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026035502/0001213900-26-035502-index.htm","comparable_excerpt":"On May 29, 2026, Lantronix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Needham & Company, LLC and Canaccord Genuity LLC, as underwriters (together, the “Underwriters”), pursuant to which the Company agreed to sell, and the Underwriters agreed to purchase, 4,166,667 shares (the “Firm Shares”) of the Company’s common stock","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1114925/000168316826004424/0001683168-26-004424-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}